Dr. Muredach Reilly Appointed Vice Dean for Clinical and Translational Research, VP&S
Muredach Reilly, MBBCh, MSCE, the current associate dean of clinical and translational research, has agreed to take on an expanded role as vice dean of clinical and translational research for the Vagelos College of Physicians and Surgeons (VP&S). In addition to this role he continues as the Herbert and Florence Irving Professor of Medicine, Director of the Irving Institute for Clinical and Translational Research, and Director of the Cardiometabolic Precision Medicine Program at Columbia University Irving Medical Center (CUIMC).
As vice dean, Dr. Reilly will oversee next steps in planning for clinical and translational research, working closely with the VP&S strategic planning effort. His new role will build upon the exceptional success of the Irving Institute for Clinical and Translational Research to advance priorities in clinical and translational research across the school, leveraging and integrating the critical initiatives led by Daichi Shimbo, MD, associate dean of research career development; Andy Lassman, MD, associate dean of clinical research compliance; and Jide Williams, MD, associate dean of community research and engagement. As we strive for greater alignment, this effort will also work closely with Michael Shelanski, MD, PhD, Jennifer Williamson, and the VP&S Office for Research, as well as SRAC, to ensure that we are able to optimize our support for all of our investigators at VP&S. We will be sharing more about these efforts in the months to come.
"I am honored to take on this new role at VP&S and excited to work with Dean Armstrong and leadership in developing new strategies for success. We all share the same vision for empowering investigators to bring about even greater scientific discoveries. Yet, there is always an opportunity to think beyond what is and develop what could be. I am committed to advancing clinical and translational research, and engaging change as a catalyst for greater discoveries and impact to benefit our patients, our communities and the world." - Dr. Muredach Reilly
The announcement was made by VP&S Dean Armstrong in her correspondence to the university, "Redesigning VP&S’s Scientific Research Enterprise: A New Advisory Committee and Vice Dean." She cited, "There has been tremendous growth in clinical and translational research at CUIMC over the past decade. For example, between 2013 and 2022, funding for human subjects research increased from $141.7 million to $405.5 million, clinical trial revenue grew from $15.3 million to $59.7 million, and new industry sponsored clinical trials increased from 216 to 360 trials."
References